Some good news: announcing Longevity2020

In these challenging times, with everyone working from home and conferences pushed-back to later this year, we had an idea: Longevity2020

While the world overcomes COVID19, work in Longevity, for many, goes on. So we thought: let’s stage a worldwide Longevity conference!

Longevity.Technology: You’re at home, so are we… so are most of the experts in Longevity. So, let’s get together. Learn, share knowledge, build our networks and take a break from Netflix.

Longevity2020 is 100% digital – we will bring together the experts, the innovators, the investors, and the curious (online) for 2.5hrs each day over 5 fascinating days.

We’ll be using the latest online event technology to provide you with an amazing experience: you’ll receive full video and media rich presentations. At the end of each session, our platform provides you with access to other delegates through unique networking software.

Pre-registration is now open now. Once we’re happy that we have our launch programme of speakers and subjects sufficiently ready we’ll switch ticketing to live. Sessions will be over 2.5 hours each day and will start: 5pm EU: 4pm UK: 11am EST: 8am PST

Here’s the outline agenda:

Monday 27 April: Rejuvenation therapies:

What’s the latest in: senolytics, gene editing, immunotherapy,  mitochondrial restoration, indication expansion, neutraceuticals, peptides, stem cells…

Tuesday 28 April: Longevity: start now

What can you be doing to address your Longevity now: supplements, metformin, mTOR, NAD+, rapamycin, biohacking, fasting, biomarker tracking, monitoring apps…

Wednesday 29 April: AI and Longevity

How is AI accelerating Longevity and where: molecule identification, pre-clinical validation, digital health, lifestyle interventions, finance…

Thursday 30 April: Longevity investing

It’s all about growing the investment category: risk management, going public, investment platforms, emerging tech:  3D bio-printing, neuroceuticals, organ growth, agetech…

Friday 01 May: Biomarkers of aging

Addressing the need for a baseline: cellular senescence, methylation, telomere length, metabolomics, inflammation, congnition, function, ageotype…


We’re just lining-up our curators and speakers. Please pre-register for updates… or apply to present! 

We hope you, your family and your colleagues are all keeping well. Our team is located in London, Paris and Berlin – we’re staying positive and trust you are too. Best wishes 🙂

Phil Newman
Editor-in-Chief Phil has over 25 years of C-level management, marketing and business development expertise in Europe and North America. His creative background has helped him shape unconventional strategies for commercial growth - garnering both awards and investor ROI.

Phil has wide experience of technology transfer and the commercialisation of innovations from both private and institutional sources and this led to his interest in Longevity and the founding of Longevity.Technology.

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down's Rejuvenation Roadmap – and it's a journey towards Longevity progress. is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...